HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene.

Abstract
We studied whether a patient with Graves' disease will go into remission during antithyroid drug (ATD) treatment. Remission of Graves' hyperthyroidism is predicted by a smooth decrease in TSH receptor antibody (TRAb) during ATD treatment. Cytotoxic T cell lymphocyte-associated molecule-4 (CTLA-4) may play an important role in the development of Graves' hyperthyroidism and in its remission. We studied A/G polymorphism at position 49 in exon 1 of the CTLA-4 gene in 144 Japanese Graves' patients. We intended to reveal the possible association of CTLA-4 gene polymorphism with the remission of Graves' hyperthyroidism. All patients with Graves' disease were treated with ATD. Thyroid-stimulating antibody and TSH binding inhibitory Ig were measured as TRAb. We analyzed CTLA-4 genotypes and alleles with PCR. We calculated the frequencies of CTLA-4 genotypes and alleles. A significant increase in the frequency of the G allele was seen in Graves' patients compared with controls (P = 0.0095). Graves' patients were divided into three groups (A, B, and C) according to time of TRAb disappearance after the start of ATD treatment. In group A patients TRAb had disappeared within 1 yr after the start of ATD treatment, in group B TRAb had disappeared between the beginning of the second year and the end of the fifth year of treatment, and in group C TRAb continued to be positive after 5 yr of ATD treatment. The frequencies of the GG genotype and the G allele were significantly higher in group C patients with persistently positive TRAb over 5 yr of ATD treatment than in the other groups (P < 0.0001). Group C patients did not have the AA genotype. The periods of time until remission were significantly shorter in the AA genotype. Graves' patients with the G allele need to continue ATD treatment for longer periods.
AuthorsYoshino Kinjo, Nobuyuki Takasu, Ichiro Komiya, Takeaki Tomoyose, Masaki Takara, Tsuyoshi Kouki, Yoshinori Shimajiri, Kouichi Yabiku, Hiroshi Yoshimura
JournalThe Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 87 Issue 6 Pg. 2593-6 (Jun 2002) ISSN: 0021-972X [Print] United States
PMID12050220 (Publication Type: Journal Article)
Chemical References
  • Antibodies
  • Antithyroid Agents
  • Receptors, Thyrotropin
Topics
  • Adolescent
  • Adult
  • Aged
  • Alleles
  • Antibodies (analysis)
  • Antithyroid Agents (therapeutic use)
  • Exons
  • Female
  • Gene Frequency
  • Genotype
  • Graves Disease (drug therapy, genetics, physiopathology)
  • Humans
  • Male
  • Middle Aged
  • Polymorphism, Genetic
  • Receptors, Thyrotropin (immunology)
  • Remission Induction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: